Fundraising FoxFibrogen
San Francisco, US · 5 known investors
Find your way into Fibrogen
Sign up to see every warm intro you have to Fibrogen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Fibrogen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions. Its pipeline includes drug candidates such as roxadustat and FG-3246.
Founders & leadership
Board
Investors · 5
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Ridgeback Capital's portfolio page · Not right? Tell us
How we know: Scientia Ventures's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$20M disclosed across 1 round · 2014
▶$20MraisedDec 2014 · 1 investors · PharmaceuticalsRule 506(b)
- Frank H. ValoneExecutive Officer
- Thomas F. KearnsDirector
- K. Peony YuExecutive Officer
- Jorma RouttiDirector
- Miguel MaderoDirector
- Rory B. RiggsDirector
- Toshinari TamuraDirector
- Kalevi KurkijarviDirector
- Julian N. SternDirector
- Thomas B. NeffExecutive Officer, Director
- James A. SchoeneckDirector
- Pat CotroneoExecutive Officer
- Roberto Pedro RosenkranzDirector
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Fibrogen went on to found or lead other companies.
Frequently asked questions
- What does Fibrogen do?
- Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions. Its pipeline includes drug candidates such as roxadustat and FG-3246.
- Who founded Fibrogen?
- Fibrogen was founded by Thomas B. Neff.
- Who are Fibrogen's investors?
- Fibrogen's investors include Avalon BioVentures, Foresite Capital, Ridgeback Capital, Scientia Ventures, Maverick Ventures.
- How much funding has Fibrogen raised?
- Fibrogen has disclosed $20M raised across 1 round.
- Where is Fibrogen headquartered?
- Fibrogen is headquartered in San Francisco, US.